Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

Clinical trial NCT06237920 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06237920
Sponsor: The Netherlands Cancer Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Urinary Bladder Diseases Male Urogenital Diseases Urinary Bladder Neoplasm Antineoplastics Toxicity

Start date: 2024-02-19
Primary completion: 2026-12-01
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.